Reshaping tumor immune microenvironment and modulating T cell function based on hierarchical nanotherapeutics for synergistically inhibiting osteosarcoma
Source abstract
Abstract
T-cell-based immunotherapy shows significant promise for treating osteosarcoma. However, its effectiveness is often limited by the immunosuppressive tumor environment and weakened T-cell activity. In this study, we present a tumor-targeting strategy that aims to reshape the tumor microenvironment and modulate T-cell function using a hierarchical metal-organic framework (MOF). The MOF is armed with PD-L1 antibody (anti-PD-L1) and loaded with C-C motif chemokine ligand 19 (CCL19) and oxaliplatin in separate layers, which enhances the therapeutic efficiency for osteosarcoma. The intricate hierarchical MOFs employed in this research provide a programmable action schedule for the loaded drugs, enabling spatiotemporal control over their release and action. The anti-PD-L1 on the surface of nanoparticles specifically binds to PD-L1 on tumor cells, reinforcing the targeting and recognition capabilities of the materials. Additionally, this targeted approach serves as an immune checkpoint inhibitors therapy, blocking the binding of PD-1 and PD-L1 between T cells and tumor cells. This prevents T-cell exhaustion, thereby restoring their killing ability. Moreover, the initial release of CCL19 from the nanoparticles recruits more T cells into the tumor microenvironment, augmenting the immunotherapy effect. As a result, when oxaliplatin is pH-responsively released from the nanoparticles upon being absorbed by osteosarcoma cells, it exhibits maximum killing ability against the cancer cells. In vivo studies demonstrated that the developed nanosystem exhibited an anti-tumor effect, resulting in a tumor suppression rate exceeding 90% while causing minimal side effects. This comprehensive approach inhibits tumor growth and metastasis with minimal side effects, demonstrating the positive efficacy of combining immunotherapy and conventional chemotherapy in osteosarcoma treatment. Furthermore, the developed nanoparticles not only have a high drug loading capacity but also prevent mutual interference between different drugs, allowing each drug to exert its optimal effect. This study introduces a promising paradigm for the field of immunochemotherapy and offers potential advancements in the treatment of osteosarcoma.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (37)
Show source-provided references
1. Enhancement of anti-PD-1/PD-L1 immunotherapy for osteosarcoma using an intelligent autophagy-controlling metal organic framework10.1016/j.biomaterials.2022.121407 ↗
2. Advancing therapy for osteosarcoma10.1038/s41571-021-00519-8 ↗
3. New Horizons in the treatment of osteosarcoma10.1056/NEJMra2103423 ↗
4. Oxaliplatin: a review of preclinical and clinical studies10.1023/A:1008213732429 ↗
5. Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer10.1038/s41416-021-01592-7 ↗
6. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies10.2165/00003495-200060040-00005 ↗
7. Clinical pharmacokinetics of oxaliplatin: a critical review
8. A combination of PD-1/PD-L1 inhibitors: the prospect of overcoming the weakness of tumor immunotherapy10.3892/mmr.2021.12001 ↗
9. Triune nanomodulator enables exhausted cytotoxic T lymphocyte rejuvenation for cancer epigenetic immunotherapy10.1021/acsnano.4c02337 ↗
10. Anticancer nanocage platforms for combined immunotherapy designed to harness immune checkpoints and deliver anticancer drugs10.1016/j.biomaterials.2021.120685 ↗
11. Celastrol nanoemulsion induces immunogenicity and downregulates PD-L1 to boost abscopal effect in melanoma therapy10.1016/j.biomaterials.2020.120604 ↗
12. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy10.1038/s41392-020-00449-4 ↗
13. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types10.1016/j.annonc.2021.02.006 ↗
14. Tumour-intrinsic resistance to immune checkpoint blockade10.1038/s41577-019-0218-4 ↗
15. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -Extrinsic factors10.1016/j.immuni.2016.06.001 ↗
16. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers10.1136/jitc-2020-001558 ↗
17. Immunotherapy for osteosarcoma: fundamental mechanism, rationale, and recent breakthroughs10.1016/j.canlet.2020.12.024 ↗
18. CCR7 and its ligands: balancing immunity and tolerance10.1038/nri2297 ↗
19. CCL19 enhances CD8(+) T-cell responses and accelerates HBV clearance10.1007/s00535-021-01799-8 ↗
20. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor10.1038/nbt.4086 ↗
21. CCR7 as a therapeutic target in cancer
22. Immune synapse instructs epigenomic and transcriptomic functional reprogramming in dendritic cells10.1126/sciadv.abb9965 ↗
23. CCL19 and CCR7 expression, signaling pathways, and adjuvant functions in viral infection and prevention10.3389/fcell.2019.00212 ↗
24. PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells10.1182/blood-2009-12-258038 ↗
25. Immobilized chemokine fields and soluble chemokine gradients cooperatively shape migration patterns of dendritic cells10.1016/j.immuni.2010.04.017 ↗
26. Powerful anticolon tumor effect of targeted gene immunotherapy using folate-modified nanoparticle delivery of CCL19 to activate the immune system10.1021/acscentsci.8b00688 ↗
27. Curcumin in osteosarcoma therapy: combining with immunotherapy, chemotherapeutics, bone tissue engineering materials and potential synergism with photodynamic therapy
28. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma10.1016/j.biomaterials.2020.120579 ↗
29. Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective10.1016/j.ebiom.2024.105301 ↗
30. Metformin-based nanomedicines for reprogramming tumor immune microenvironment10.7150/thno.104872 ↗
31. Nanoscale metal-organic frameworks for cancer immunotherapy10.1021/acs.accounts.0c00313 ↗
32. Immune-regulating bimetallic metal-organic framework nanoparticles designed for cancer immunotherapy10.1016/j.biomaterials.2021.121261 ↗
33. Recent development of metal-organic framework nanocomposites for biomedical applications10.1016/j.biomaterials.2021.121322 ↗
34. The chemistry and applications of metal-organic frameworks10.1126/science.1230444 ↗
35. Tailoring metal-organic frameworks-based nanozymes for bacterial theranostics10.1016/j.biomaterials.2021.120951 ↗
36. Biomimetic nanoreactor for targeted cancer starvation therapy and Cascade amplificated chemotherapy10.1016/j.biomaterials.2021.120869 ↗
37. Correction to "Reversing Chemotherapy Resistance by a Synergy between Lysosomal pH-Activated Mitochondrial Drug Delivery and Erlotinib-Mediated Drug Efflux Inhibition"10.1021/acsami.2c04966 ↗